Welcome

Rare bleeding disorders have a huge impact on women’s lives.

Watch this expert-led, case-based webcast where our global faculty discuss the unmet needs in the identification and management of rare bleeding disorders in women and girls, with both pediatric and obstetric examples.

The live broadcast was on 22nd March 2022. 

This CME-accredited webcast is suitable for global hematologists, pediatric hematologists, obstetricians/gynecologists, and primary care practitioners.

Learning objectives

After participating in the live webinar learners will be able to:

  • Identify the hallmark signs of rare bleeding disorders in women
  • Debate the key barriers to early diagnosis and referral of rare bleeding disorders in women
  • Explain how early diagnosis and timely referral can achieve optimum management

Funding

This program is made possible thanks to an independent educational grant from Novo Nordisk Health Care AG.

Chapters

Welcome

Welcome

Welcome and introductions to the webcast

Watch
Unmet needs

Presentation

Unmet needs in the identification and management of rare bleeding disorders in women

Watch
Case 1

Case 1

Pediatric/adolescent case of girl with heavy menstrual bleeding: reaching a diagnosis and appropriate management.

Watch
Case 2

Case 2

Obstetric case of woman with post-partum bleeding: reaching a diagnosis and appropriate management.

Watch
Closing Remarks

Summary and close

Closing remarks 

Watch

AGENDA

Time Presentation Presenter(s)
5 min Welcome Roseline d’Oiron
10 min Unmet needs in the identification and management of rare bleeding disorders in women Roseline d’Oiron
- Practical approaches to achieving earlier diagnosis and referral, and optimum care: Case presentations
20 min CASE 1
Pediatric/adolescent case of girl with heavy menstrual bleeding
Stacy Croteau
20 min CASE 2
Obstetric case of woman with post-partum bleeding
Rezan Abdul-Kadir
5 min Summary and close Roseline d’Oiron

Faculty

Dr Roseline D’Oiron

Roseline d’Oiron is currently a medical director at the Reference Centre for Haemophilia and Rare Congenital Bleeding Disorders, at APHP Université Paris Saclay, Hôpital Bicêtre, 94270 Le Kremlin–Bicêtre, France. Dr d’Oiron graduated as a medical doctor from UFR Broussais-Hôtel-Dieu, University Paris VI, and completed her specialty training with master’s degrees in hematology, immunology, immunopathology, and transfusion medicine from UFR Saint-Antoine, University Paris VI.

Read more

Dr Roseline D’Oiron

Roseline d’Oiron is currently a medical director at the Reference Centre for Haemophilia and Rare Congenital Bleeding Disorders, at APHP Université Paris Saclay, Hôpital Bicêtre, 94270 Le Kremlin–Bicêtre, France.

Dr d’Oiron graduated as a medical doctor from UFR Broussais-Hôtel-Dieu, University Paris VI, and completed her specialty training with master’s degrees in hematology, immunology, immunopathology, and transfusion medicine from UFR Saint-Antoine, University Paris VI.

Her research interests are principally in the area of hemophilia and rare bleeding disorders in both children and adults, especially regarding issues on molecular mechanisms of hemophilia A, inhibitors, immune tolerance, mild/moderate hemophilia, carriers of hemophilia, women with bleeding disorders and Glanzmann’s thrombasthenia.

Dr d’Oiron is the current elected president of the steering committee of the national FranceCoag registry on bleeding disorders. Dr d’Oiron is also a former elected member of the European Association for Haemophilia and Allied Disorders (EAHAD) Executive Committee. With the National Federation of Patients, she has developed outreach programs dedicated to women from families with hemophilia and rare bleeding disorders.

Roseline D’Oiron discloses the following relationships and financial interests. Grant or Research Support (to Hôpitaux Universitaires Paris-Sud, site Bicêtre, APHP) from Baxalta/Shire, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche and SOBI. Roseline also declares that she is on the advisory board or has been an invited speaker at symposia for the following companies Baxalta/Shire/Takeda, Bayer, Biomarin, CSL Behring, LFB, NovoNordisk, Octapharma, Pfizer, Roche, SOBI and Spark.

Dr Stacy Croteau

Dr Stacy Croteau is a pediatric hematologist and clinical investigator at Boston Children’s Hospital and an assistant professor of pediatrics at Harvard Medical School, where she specializes in bleeding and clotting disorders. Dr Croteau is the head of the Hemophilia/VWD program at Boston Children’s Hospital and Medical Director for the Boston Hemophilia Center serving Boston Children’s Hospital and Brigham and Women’s Hospital. Dr Croteau currently serves as the principal investigator for several industry-sponsored and investigator-initiated clinical trials on hemophilia and other bleeding and clotting disorders.

Read more

Dr Stacy Croteau

Dr Croteau is a pediatric hematologist and clinical investigator at Boston Children’s Hospital and an assistant Professor of Pediatrics at Harvard Medical School, where she specializes in bleeding and clotting disorders. Dr Croteau is the head of the Hemophilia/VWD program at Boston Children’s Hospital and Medical Director for the Boston Hemophilia Center serving Boston Children’s Hospital and Brigham and Women’s Hospital. Dr Croteau currently serves as the principal investigator for several industry-sponsored and investigator-initiated clinical trials on hemophilia and other bleeding and clotting disorders.

Dr Stacy Croteau discloses the following relationships and financial interests. Consultancy fees obtained from Biomarin, Bayer, CSL-Behring, Hema Biologics, Pfizer and Sanofi. Stacy is also on the Board of Directors for the Hemophilia Alliance.
All relevant financial relationships have been mitigated

Dr Rezan Abdul-Kadir

Rezan Abdul Kadir is a doctor and consultant obstetrician and gynecologist at the Royal Free Hospital in London and University College London, UK. She is also a specialist consultant in women with bleeding disorders and set up the first multi-disciplinary clinic to provide comprehensive care for women and families with bleeding disorders. This clinic is renowned nationally and internationally for providing training and leading clinical and laboratory projects in this field.

Read more

Dr Rezan Abdul-Kadir

Rezan Abdul Kadir is a doctor and consultant obstetrician and gynecologist at the Royal Free Hospital in London and University College London, UK. She is also a specialist consultant in women with bleeding disorders and set up the first multi-disciplinary clinic to provide comprehensive care for women and families with bleeding disorders. This clinic is renowned nationally and internationally for providing training and leading clinical and laboratory projects in this field.

Dr Abdul Kadir edited “Inherited Bleeding Disorders in Women” book; first edition published in 2009 and second edition in 2019. She has authored /co-authored over two hundred peer-reviewed publications and written national and international guidelines in the field of thrombosis and haemostasis in women. She has acted as a guest editor and a reviewer for several journals, including Haemophilia, JTH, STH, IJOG. O&G, JOG and others. Dr Abdul Kadir is currently a co-chair of women's SSC committee of ISTH, a member of women committee of WFH and EAHAD and a member of advisory board for the UK Haemophilia Society and EHC.

Professor Rezan Abdul-Kadir has no competing interests to disclose.
All relevant financial relationships have been mitigated.

Accreditation

Accreditation logo

In support of improving patient care, this activity has been planned and implemented by HMP Education and Springer Healthcare IME. HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

HMP Education designates this webcast for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to claim your credits

To claim your credits for participating in the accredited activities, you will need to fill out a short evaluation form and select the box to collect your certificate.

Planning committee

In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include: Greaton Sellers, Jaia Barratt & Rebecca Cox. 

Greaton Sellers, Jaia Barratt and Rebecca Cox have no financial relationships to disclose.

Evaluation

Quick feedback:

Please complete our feedback form as this helps us to design the most relevant educational programs for you. Should you wish to claim AMA PRA Category 1 credits™ for your participation in activity, please select claim credits (Yes) and make sure all fields below are completed. Should you not wish to claim credits but you would still like to provide us with valuable feedback, please simply fill out the form and click submit.

Please enter your name. If claming credits this will appear on your certificate.
Country
I would like to claim credits

Certificate of Attendance

Please complete the fields below and fill out the feedback form before collecting your certificate.

Please enter your degree as you would like it to appear on your certificate
1) Please rate the following: (1=poor, 10=excellent)
a) Overall quality of this webcast
b) Design and format
c) Presentation 1. Unmet needs in the identification and management of rare bleeding disorders in women
d) Case 1. Pediatric/adolescent case of girl with heavy menstrual bleeding: reaching a diagnosis and appropriate management
e) Case 2. Obstetric case of woman with post-partum bleeding: reaching a diagnosis and appropriate management
2) How well did the learning activity fulfil the following learning objectives?
After this webcast, I am able to:
Identify the hallmark signs of various rare bleeding disorders in women
Debate the key barriers to early diagnosis and referral of rare bleeding disorders in women
Explain how early diagnosis and timely referral can achieve optimum management
3) This activity:
 
Was based on relevant and current/new evidence
Has increased my knowledge of the subject
Has increased my confidence in this subject
Was focused on competencies relevant to my practice
Will help me improve patient care within my clinical practice
4) Learning impact
Following this webcast will you make any measurable changes in your practice?
Select the following changes you are likely to make:
5) Bias
Did you feel there was any bias in the educational content?
6) Would you recommend this webcast to a colleague?
7) Share your thoughts on relevant learning programs